{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:59:41Z","timestamp":1794621581135,"version":"4.9.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunomodulatory properties of histone deacetylase inhibitors represent a reasonable approach for acute graft-versus-host disease (aGVHD) prevention. We report a phase 2 trial evaluating panobinostat (PANO) administered over 26 weeks, starting on day \u22125 (5 mg orally 3 times a week) with tacrolimus initiated on day \u22123 plus sirolimus on day \u22121, with a median patient age of 58 years (range, 19-72 years) (n = 38). Donor source consisted of HLA 8\/8\u2013matched donors, related (n = 13) or unrelated (n = 25), using granulocyte colony-stimulating factor\u2013stimulated peripheral blood stem cells. Myeloablative (n = 18) or reduced-intensity (n = 20) conditioning regimens were used for patients with acute myeloid leukemia (n = 17), myelodysplastic syndrome (n = 13), or other malignancies (n = 8). The cumulative incidence of aGVHD II-IV by day 100 was 18.4% (90% confidence interval [CI], 9.4% to 29.9%). Cumulative incidence of chronic GVHD at 1 year was 31.6% (90% CI, 19.5% to 44.3%). Adverse events related to PANO were thrombocytopenia (n = 5), leukopenia (n = 6), gastrointestinal toxicity (n = 3), rash (n = 4), renal failure\/peripheral edema (n = 1), and periorbital edema (n = 1). At 1 year, overall survival was 89.5% (90% CI, 81.6% to 98.0%), relapse-free survival was 78.9% (90% CI, 68.8% to 90.6%), nonrelapse mortality was 2.6% (90% CI, 0.3% to 9.9%), and GVHD relapse-free survival was 60.5% (90% CI, 48.8% to 75.1%). PANO hits histone 3 as early as day 15 in CD8, CD4 and T regs. In conclusion, PANO combination met the primary study end point for aGVHD prevention and warrants further testing. This trial was registered at www.clinicaltrials.gov as #NCT02588339.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004225","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T01:04:37Z","timestamp":1625879077000},"page":"2740-2750","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention"],"prefix":"10.1182","volume":"5","author":[{"given":"Lia","family":"Perez","sequence":"first","affiliation":[{"name":"Blood & Marrow Transplant & Cellular Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7322-0392","authenticated-orcid":false,"given":"Hugo","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Blood & Marrow Transplant & Cellular Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"Blood & Marrow Transplant & Cellular Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Khimani","sequence":"additional","affiliation":[{"name":"Blood & Marrow Transplant & Cellular Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Betts","sequence":"additional","affiliation":[{"name":"Blood & Marrow Transplant & Cellular Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Mishra","sequence":"additional","affiliation":[{"name":"Blood & Marrow Transplant & Cellular Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[{"name":"Blood & Marrow Transplant & Cellular Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"Blood & Marrow Transplant & Cellular Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonel","family":"Ochoa-Bayona","sequence":"additional","affiliation":[{"name":"Blood & Marrow Transplant & Cellular Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nieder","sequence":"additional","affiliation":[{"name":"Blood & Marrow Transplant & Cellular Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3800-2645","authenticated-orcid":false,"given":"Joseph","family":"Pidala","sequence":"additional","affiliation":[{"name":"Blood & Marrow Transplant & Cellular Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Achille","sequence":"additional","affiliation":[{"name":"Immunology Program, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Powers","sequence":"additional","affiliation":[{"name":"Immunology Program, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-2275","authenticated-orcid":false,"given":"Eva","family":"Sahakian","sequence":"additional","affiliation":[{"name":"Immunology Program, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Thapa","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5775-408X","authenticated-orcid":false,"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Anasetti","sequence":"additional","affiliation":[{"name":"Blood & Marrow Transplant & Cellular Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"issue":"1","key":"2021070922552982200_B1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2016-08-686659","article-title":"Mechanistic approaches for the prevention and treatment of chronic GVHD","volume":"129","author":"Cutler","year":"2017","journal-title":"Blood."},{"issue":"4","key":"2021070922552982200_B2","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.21873\/anticanres.11483","article-title":"Acute graft versus host disease: a comprehensive review","volume":"37","author":"Nassereddine","year":"2017","journal-title":"Anticancer Res."},{"issue":"16","key":"2021070922552982200_B3","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med."},{"issue":"12","key":"2021070922552982200_B4","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3324\/haematol.2012.067140","article-title":"A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation","volume":"97","author":"Pidala","year":"2012","journal-title":"Haematologica."},{"issue":"5","key":"2021070922552982200_B5","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1073\/pnas.052702999","article-title":"The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines","volume":"99","author":"Leoni","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"2021070922552982200_B6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI16153","article-title":"Histone deacetylase inhibitors modulate renal disease in the MRL-lpr\/lpr mouse","volume":"111","author":"Mishra","year":"2003","journal-title":"J Clin Invest."},{"issue":"11","key":"2021070922552982200_B7","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/nm1652","article-title":"Deacetylase inhibition promotes the generation and function of regulatory T cells","volume":"13","author":"Tao","year":"2007","journal-title":"Nat Med."},{"issue":"13","key":"2021070922552982200_B8","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1158\/1078-0432.CCR-06-2903","article-title":"Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity","volume":"13","author":"Nencioni","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2021070922552982200_B9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-10-1198","article-title":"Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation","volume":"17","author":"Tawara","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2021070922552982200_B10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/leu.2010.244","article-title":"HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells","volume":"25","author":"Song","year":"2011","journal-title":"Leukemia."},{"issue":"1","key":"2021070922552982200_B11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(13)70512-6","article-title":"Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1\/2 trial","volume":"15","author":"Choi","year":"2014","journal-title":"Lancet Oncol."},{"issue":"15","key":"2021070922552982200_B12","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood-2017-06-790469","article-title":"Vorinostat plus tacrolimus\/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT","volume":"130","author":"Choi","year":"2017","journal-title":"Blood."},{"issue":"1","key":"2021070922552982200_B13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer."},{"issue":"9","key":"2021070922552982200_B14","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene."},{"issue":"11","key":"2021070922552982200_B15","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol."},{"issue":"7","key":"2021070922552982200_B16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1586\/14737140.2015.1047770","article-title":"Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma [published correction appears in Expert Rev Anticancer Ther. 2015;15:1121]","volume":"15","author":"Richardson","year":"2015","journal-title":"Expert Rev Anticancer Ther."},{"issue":"11","key":"2021070922552982200_B17","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/leu.2017.242","article-title":"Phase I\/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)","volume":"31","author":"Bug","year":"2017","journal-title":"Leukemia."},{"issue":"22","key":"2021070922552982200_B18","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood.V128.22.832.832","article-title":"Early post-transplant epigenetic therapy by panobinostat and decitabine followed by donor lymphocyte infusion (DLI): interim results of the HOVON-116 phase I\/II feasibility study in poor-risk AML recipients of allogeneic stem cell transplantation (alloHSCT)","volume":"128","author":"Cornelissen","year":"2016","journal-title":"Blood."},{"issue":"1","key":"2021070922552982200_B19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bjh.17080","article-title":"Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma","volume":"193","author":"Mithraprabhu","year":"2021","journal-title":"Br J Haematol."},{"issue":"7","key":"2021070922552982200_B20","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3324\/haematol.2015.123588","article-title":"Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease","volume":"100","author":"Pidala","year":"2015","journal-title":"Haematologica."},{"issue":"11","key":"2021070922552982200_B21","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41409-018-0163-z","article-title":"Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease","volume":"53","author":"Perez","year":"2018","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"2021070922552982200_B22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation."},{"issue":"12","key":"2021070922552982200_B23","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant."},{"issue":"23","key":"2021070922552982200_B24","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1182\/blood.V126.23.4344.4344","article-title":"Phase I\/II study of the deacetylase inhibitor panobinostat as maintenance therapy after an allogeneic stem cell transplantation in patients with high-risk MDS or AML: the panobest-trial","volume":"126","author":"Bug","year":"2015","journal-title":"Blood."},{"issue":"6","key":"2021070922552982200_B25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa1213299","article-title":"ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death","volume":"369","author":"Vander Lugt","year":"2013","journal-title":"N Engl J Med."},{"issue":"25","key":"2021070922552982200_B26","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1182\/blood-2011-08-375006","article-title":"Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease","volume":"118","author":"Ferrara","year":"2011","journal-title":"Blood."},{"issue":"12","key":"2021070922552982200_B27","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"issue":"15","key":"2021070922552982200_B28","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood-2017-06-790469","article-title":"Vorinostat plus tacrolimus\/methotrexate to prevent GVHD following myeloablative conditioning unrelated donor HCT","volume":"130","author":"Choi","year":"2017","journal-title":"Blood."},{"issue":"8","key":"2021070922552982200_B29","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/leu.2013.38","article-title":"Phase Ia\/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies","volume":"27","author":"DeAngelo","year":"2013","journal-title":"Leukemia."},{"issue":"9","key":"2021070922552982200_B30","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/13543784.2013.815165","article-title":"Panobinostat in lymphoid and myeloid malignancies","volume":"22","author":"Khot","year":"2013","journal-title":"Expert Opin Investig Drugs."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/13\/2740\/1813681\/advancesadv2021004225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/13\/2740\/1813681\/advancesadv2021004225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T01:04:59Z","timestamp":1625879099000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/13\/2740\/476279\/A-phase-2-trial-of-the-histone-deacetylase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":30,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,7,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004225","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]}}}